Gallium-67 scanning for carcinoma of the lung

DeMeester, Tom R.; Bekerman, Carlos; Joseph, J.; Toscano, M.S.; Golomb, Harvey M.; Bitran, Jacob D.; Gross, Nicholas J.; Skinner, David B.

doi:10.1016/s0022-5223(19)39617-5

Cited by 58 publications

(3 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our preliminary observations suggest that the agent is most useful for classifying normal lymph nodes. EVALUATING REGIONAL AND DISTANT lymph nodes provides crucial information for treatment planning and prognosis in patients with known cancer (1,2). Although CT and MRI are extremely sensitive in detecting the presence of lymph nodes, native density or signal intensity evaluation does not reliably distinguish benign from malignant lymph nodes.…”

mentioning

confidence: 99%

MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (combidex): Preliminary observations

Harisinghani

Saini

Slater

et al. 1997

Magnetic Resonance Imaging

View full text Add to dashboard Cite

The potential of ultrasmall superparamagnetic iron oxide (Combidex)-enhanced MRI of pelvic lymph nodes in patients with primary pelvic carcinoma is evaluated. Fifteen histologically classified lymph nodes in six patients with known primary pelvic cancer (four prostate; one rectum; one uterus) were evaluated with T2-weighted fast spin-echo (FSE) and T2*-weighted gradient-echo (GRE) MRI at 1.5T 12 to 48 hours after intravenous administration of Combidex at a dose of 1.7 mg Fe/kg. Quantitative image evaluation was performed by comparing signal intensity of individual nodes on pre- and postcontrast images. All patients proceeded to pelvic lymph-node biopsy or surgical dissection, where six were found to be benign and nine were malignant. Of the 15 lymph nodes, four nodes showed a decrease in signal intensity. Of these, three, in which signal loss was homogenous were benign, and one, in which the signal-intensity decrease was heterogeneous, was malignant (micrometastases). No signal change was noted in 11 of 15 lymph nodes of which three were benign (inflammatory) and eight were malignant. Combidex is a promising MR contrast agent for evaluating pelvic lymph nodes. Our preliminary observations suggest that the agent is most useful for classifying normal lymph nodes.

show abstract

mentioning

confidence: 99%

MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (combidex): Preliminary observations

Harisinghani

Saini

Slater

et al. 1997

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

“…Chemotherapy courses were repeated every 28 days, except in the CAML-HC regimen in which a CAML cycle would begin six weeks after an HC cycle. After two cycles of chemotherapy in all regimens, radiation therapy was instituted, consisting of 3000 rads in [10][11][12][13][14][15] 200-rad fractions to the primary lung lesion, hilar lymph nodes, mediastinum, and supraclavicular fossa if supraclavicular nodes were involved. After a 7-14 day rest, chemotherapy was resumed.…”

Section: Methodsmentioning

confidence: 99%

“…The seventh biennial program on current methods of immunologic research and diagnosis will be offered by The Ernest Witebsky Center for Immunology of the State University of New York at Buffalo June [1][2][3][4][5][6][7][8][9][10][11][12][13]1981. This will consist primarily of a combination of core and elective practical laboratory exercises to allow the participant to become acquainted with the techniques by personally carrying them out at the bench complemented by demonstrations, lectures, and discussions.…”

Section: Seventh Summer Program In Methods Of Immunologic Research Anmentioning

confidence: 99%

Small-cell carcinoma of the lung: A five-year experience with combined modality therapy

Hoffman

Golomb

Bitran

et al. 1980

Cancer

View full text Add to dashboard Cite

In the past five years, we have treated 89 patients with small-cell carcinoma of the lung with radio-therapy plus one of three chemotherapy programs. The 24 patients with disease confined to the chest (Stage IIIMo) had an 87% response rate to the combined modalities (79% complete responses) and a median survival of 18 months; 13 patients with disease confined to the chest and ipsilateral supraclavic-ular nodes (Stage IIIMoSCN+) had an 84% response rate (69% complete reponses) and 11-month median survival; the 52 patients with distant metastases (Stage IIIMI) had a 71% response rate (15% complete responses) and eight-month median survival. Survival was not affected by adding pro-phylactic cranial irradiation to the latest regimen, although the CNS relapse rate was reduced. We conclude that our three chemotherapy programs to date differ very little in their effect on survival of patients with metastatic disease. New and more vigorous approaches, possibly including surgery, need to be tested for the management of disease confined to the chest. The designation of patients as Stage III,,SCN+ is valid because such patients have better survival rates than patients with distant metastatic disease. Cancer 46:2550-2556. 1980. MALL-CELL CARCINOMA of lung is a disease S with very poor survival rates and for which the local modalities of surgery and radiotherapy have little impact on mortality.25 In the past decade, major advances have been made in the management of this tumor, principally due to the addition of combination chemotherapy programs to local modalities of treatment. These advances have been summarized in several recent reviews.7~16~23~27 Beginning in 1974, patients at the University of Chicago and Michael Reese Medical Center with small-cell bronchogenic carcinoma have been treated aggressively with a series of three successive programs combining radiation therapy and chemotherapy. Our results with 51 patients with two of the programs have been reported previously.5,10 In this paper we report the results of treatment of 38 additional patients with a third program, compare the three programs, and sum

show abstract

Thoracic Computed Tomography in the Preoperative Evaluation of Primary Bronchogenic Carcinoma

Matthews¹,

Richey²,

Helsel³

et al. 1987

Arch Intern Med

View full text Add to dashboard Cite

Gallium-67 scanning for carcinoma of the lung

Cited by 58 publications

References 2 publications

MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (combidex): Preliminary observations

MR imaging of pelvic lymph nodes in primary pelvic carcinoma with ultrasmall superparamagnetic iron oxide (combidex): Preliminary observations

Small-cell carcinoma of the lung: A five-year experience with combined modality therapy

Thoracic Computed Tomography in the Preoperative Evaluation of Primary Bronchogenic Carcinoma

Contact Info

Product

Resources

About